Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Immunity ; 42(6): 1033-47, 2015 Jun 16.
Artículo en Inglés | MEDLINE | ID: mdl-26084023

RESUMEN

Expansion and acquisition of Th1 cell effector function requires metabolic reprogramming; however, the signals instructing these adaptations remain poorly defined. Here we found that in activated human T cells, autocrine stimulation of the complement receptor CD46, and specifically its intracellular domain CYT-1, was required for induction of the amino acid (AA) transporter LAT1 and enhanced expression of the glucose transporter GLUT1. Furthermore, CD46 activation simultaneously drove expression of LAMTOR5, which mediated assembly of the AA-sensing Ragulator-Rag-mTORC1 complex and increased glycolysis and oxidative phosphorylation (OXPHOS), required for cytokine production. T cells from CD46-deficient patients, characterized by defective Th1 cell induction, failed to upregulate the molecular components of this metabolic program as well as glycolysis and OXPHOS, but IFN-γ production could be reinstated by retrovirus-mediated CD46-CYT-1 expression. These data establish a critical link between the complement system and immunometabolic adaptations driving human CD4(+) T cell effector function.


Asunto(s)
Proteínas del Sistema Complemento/inmunología , Síndrome Hemolítico-Urémico/inmunología , Transportador de Aminoácidos Neutros Grandes 1/metabolismo , Proteína Cofactora de Membrana/metabolismo , Células TH1/fisiología , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Diferenciación Celular/inmunología , Células Cultivadas , Reprogramación Celular/inmunología , Transportador de Glucosa de Tipo 1/genética , Transportador de Glucosa de Tipo 1/metabolismo , Glucólisis , Proteínas de Homeodominio/metabolismo , Humanos , Inmunidad Celular/genética , Interferón gamma/metabolismo , Diana Mecanicista del Complejo 1 de la Rapamicina , Proteína Cofactora de Membrana/genética , Proteínas de Unión al GTP Monoméricas/metabolismo , Complejos Multiproteicos/metabolismo , Neuropéptidos/metabolismo , Fosforilación Oxidativa , ARN Interferente Pequeño/genética , Proteína Homóloga de Ras Enriquecida en el Cerebro , Serina-Treonina Quinasas TOR/metabolismo , Regulación hacia Arriba
2.
Eur J Immunol ; 46(7): 1563-73, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27184294

RESUMEN

The inflammasomes are intracellular multiprotein complexes that induce and regulate the generation of the key pro-inflammatory cytokines IL-1ß and IL-18 in response to infectious microbes and cellular stress. The activation of inflammasomes involves several upstream signals including classic pattern or danger recognition systems such as the TLRs. Recently, however, the activation of complement receptors, such as the anaphylatoxin C3a and C5a receptors and the complement regulator CD46, in conjunction with the sensing of cell metabolic changes, for instance increased amino acid influx and glycolysis (via mTORC1), have emerged as additional critical activators of the inflammasome. This review summarizes recent advances in our knowledge about complement-mediated inflammasome activation, with a specific focus on a novel "complement - metabolism - NLRP3 inflammasome axis."


Asunto(s)
Proteínas del Sistema Complemento/inmunología , Metabolismo Energético , Sistema Inmunológico/citología , Sistema Inmunológico/fisiología , Inflamasomas/metabolismo , Animales , Activación de Complemento , Proteínas del Sistema Complemento/metabolismo , Humanos , Inmunomodulación , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Transducción de Señal
4.
Cancer Immunol Res ; 12(7): 800-813, 2024 Jul 02.
Artículo en Inglés | MEDLINE | ID: mdl-38657223

RESUMEN

Chemotherapeutics, radiation, targeted therapeutics, and immunotherapeutics each demonstrate clinical benefits for a small subset of patients with solid malignancies. Immune cells infiltrating the tumor and the surrounding stroma play a critical role in shaping cancer progression and modulating therapy response. They do this by interacting with the other cellular and molecular components of the tumor microenvironment. Spatial multi-omics technologies are rapidly evolving. Currently, such technologies allow high-throughput RNA and protein profiling and retain geographical information about the tumor microenvironment cellular architecture and the functional phenotype of tumor, immune, and stromal cells. An in-depth spatial characterization of the heterogeneous tumor immune landscape can improve not only the prognosis but also the prediction of therapy response, directing cancer patients to more tailored and efficacious treatments. This review highlights recent advancements in spatial transcriptomics and proteomics profiling technologies and the ways these technologies are being applied for the dissection of the immune cell composition in solid malignancies in order to further both basic research in oncology and the implementation of precision treatments in the clinic.


Asunto(s)
Neoplasias , Medicina de Precisión , Microambiente Tumoral , Humanos , Medicina de Precisión/métodos , Neoplasias/inmunología , Neoplasias/terapia , Microambiente Tumoral/inmunología , Proteómica/métodos , Animales , Inmunoterapia/métodos , Transcriptoma
5.
Cancer Res ; 83(17): 2873-2888, 2023 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-37350667

RESUMEN

Current treatment for patients with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy (nCT), alone or combined with radiotherapy, before surgery. However, fewer than 30% of treated patients show a pathologic complete response to nCT, which correlates with increased 5-year survival compared with nonresponders. Understanding the mechanisms of response to nCT is pivotal to better stratify patients and inform more efficacious therapies. Here, we investigated the immune mechanisms involved in nCT response by multidimensional profiling of pretreatment tumor biopsies and blood from 68 patients with EAC (34 prospectively and 34 retrospectively collected), comparing complete responders versus nonresponders to nCT. At the tumor level, complete response to nCT was associated with molecular signatures of immune response and proliferation, increased putative antitumor tissue-resident memory CD39+ CD103+ CD8+ T cells, and reduced immunosuppressive T regulatory cells (Treg) and M2-like macrophages. Systemically, complete responders showed higher frequencies of immunostimulatory CD14+ CD11c+ HLA-DRhigh cells, and reduced programmed cell death ligand 1-positive (PD-L1+) monocytic myeloid-derived suppressor cells, along with high plasma GM-CSF (proinflammatory) and low IL4, CXCL10, C3a, and C5a (suppressive). Plasma proinflammatory and suppressive cytokines correlated directly and inversely, respectively, with the frequency of tumor-infiltrating CD39+ CD103+ CD8+ T cells. These results suggest that preexisting immunity in baseline tumor drives the clinical activity of nCT in locally advanced EAC. Furthermore, it may be possible to stratify patients based on predictive immune signatures, enabling tailored neoadjuvant and/or adjuvant regimens. SIGNIFICANCE: Multidimensional profiling of pretreatment esophageal adenocarcinoma shows patient response to nCT is correlated with active preexisting immunity and indicates molecular pathways of resistance that may be targeted to improve clinical outcomes.


Asunto(s)
Adenocarcinoma , Neoplasias Esofágicas , Humanos , Terapia Neoadyuvante , Estudios Retrospectivos , Adenocarcinoma/patología , Neoplasias Esofágicas/patología
6.
Life Sci Alliance ; 2(3)2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-31097471

RESUMEN

A fast antibody response can be critical to contain rapidly dividing pathogens. This can be achieved by the expansion of antigen-specific B cells in response to T-cell help followed by differentiation into plasmablasts. MicroRNA-155 (miR-155) is required for optimal T-cell-dependent extrafollicular responses via regulation of PU.1, although the cellular processes underlying this defect are largely unknown. Here, we show that miR-155 regulates the early expansion of B-blasts and later on the survival and proliferation of plasmablasts in a B-cell-intrinsic manner, by tracking antigen-specific B cells in vivo since the onset of antigen stimulation. In agreement, comparative analysis of the transcriptome of miR-155-sufficient and miR-155-deficient plasmablasts at the peak of the response showed that the main processes regulated by miR-155 were DNA metabolic process, DNA replication, and cell cycle. Thus, miR-155 controls the extent of the extrafollicular response by regulating the survival and proliferation of B-blasts, plasmablasts and, consequently, antibody production.


Asunto(s)
Subgrupos de Linfocitos B/metabolismo , MicroARNs/genética , Células Plasmáticas/metabolismo , Animales , Formación de Anticuerpos/genética , Formación de Anticuerpos/inmunología , Subgrupos de Linfocitos B/inmunología , Biomarcadores , Proliferación Celular , Supervivencia Celular/genética , Inmunofenotipificación , Activación de Linfocitos/genética , Activación de Linfocitos/inmunología , Ratones , Ratones Noqueados , Células Plasmáticas/inmunología
7.
Nat Commun ; 9(1): 4186, 2018 10 10.
Artículo en Inglés | MEDLINE | ID: mdl-30305631

RESUMEN

The induction of human CD4+ Th1 cells requires autocrine stimulation of the complement receptor CD46 in direct crosstalk with a CD4+ T cell-intrinsic NLRP3 inflammasome. However, it is unclear whether human cytotoxic CD8+ T cell (CTL) responses also rely on an intrinsic complement-inflammasome axis. Here we show, using CTLs from patients with CD46 deficiency or with constitutively-active NLRP3, that CD46 delivers co-stimulatory signals for optimal CTL activity by augmenting nutrient-influx and fatty acid synthesis. Surprisingly, although CTLs express NLRP3, a canonical NLRP3 inflammasome is not required for normal human CTL activity, as CTLs from patients with hyperactive NLRP3 activity function normally. These findings establish autocrine complement and CD46 activity as integral components of normal human CTL biology, and, since CD46 is only present in humans, emphasize the divergent roles of innate immune sensors between mice and men.


Asunto(s)
Linfocitos T CD8-positivos/inmunología , Ácidos Grasos/metabolismo , Proteína Cofactora de Membrana/metabolismo , Receptores de Complemento/metabolismo , Comunicación Autocrina , Linfocitos T CD4-Positivos/inmunología , Síndromes Periódicos Asociados a Criopirina/inmunología , Síndromes Periódicos Asociados a Criopirina/patología , Humanos , Activación de Linfocitos/inmunología , Modelos Biológicos , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Receptores de Antígenos de Linfocitos T/metabolismo , Transducción de Señal , Linfocitos T Citotóxicos/inmunología
8.
Mol Immunol ; 89: 2-9, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28601357

RESUMEN

The complement system was defined over a century ago based on its ability to "complement" the antibody-mediated and cell-mediated immune responses against pathogens. Today our understanding of this ancient part of innate immunity has changed substantially and we know now that complement plays an undisputed pivotal role in the regulation of both innate and adaptive immunity. The complement system consists of over 50 blood-circulating, cell-surface expressed and intracellular proteins. It is key in the recognition and elimination of invading pathogens, also in the removal of self-derived danger such as apoptotic cells, and it supports innate immune responses and the initiation of the general inflammatory reactions. The long prevailing classic view of complement was that of a serum-operative danger sensor and first line of defence system, however, recent experimental and clinical evidences have demonstrated that "local" tissue and surprisingly intracellular complement (the complosome) activation impacts on normal cell physiology. This review will focus on novel aspects of intracellular complement activation and its unexpected roles in basic cell processes such as metabolism. We also discuss what the existence of the complosome potentially means for how the host handles intracellular pathogens such as viruses.


Asunto(s)
Activación de Complemento/inmunología , Proteínas del Sistema Complemento/inmunología , Citoplasma/inmunología , Linfocitos T/inmunología , Inmunidad Adaptativa/inmunología , Animales , Proteínas del Sistema Complemento/metabolismo , Citoplasma/metabolismo , Humanos , Inmunidad Celular/inmunología , Inmunidad Innata/inmunología , Modelos Inmunológicos , Linfocitos T/metabolismo
9.
J Clin Invest ; 126(1): 377-88, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26657861

RESUMEN

The production of high-affinity antibodies by B cells is essential for pathogen clearance. Antibody affinity for antigen is increased through the affinity maturation in germinal centers (GCs). This is an iterative process in which B cells cycle between proliferation coupled with the acquisition of mutations and antigen-based positive selection, resulting in retention of the highest-affinity B cell clones. The posttranscriptional regulator microRNA-155 (miR-155) is critical for efficient affinity maturation and the maintenance of the GCs; however, the cellular and molecular mechanism by which miR-155 regulates GC responses is not well understood. Here, we utilized a miR-155 reporter mouse strain and showed that miR-155 is coexpressed with the proto-oncogene encoding c-MYC in positively selected B cells. Functionally, miR-155 protected positively selected c-MYC+ B cells from apoptosis, allowing clonal expansion of this population, providing an explanation as to why Mir155 deletion impairs affinity maturation and promotes the premature collapse of GCs. We determined that miR-155 directly inhibits the Jumonji family member JARID2, which enhances B cell apoptosis when overexpressed, and thereby promotes GC B cell survival. Our findings also suggest that there is cooperation between c-MYC and miR-155 during the normal GC response, a cooperation that may explain how c-MYC and miR-155 can collaboratively function as oncogenes.


Asunto(s)
Apoptosis , Linfocitos B/fisiología , MicroARNs/fisiología , Proteínas Proto-Oncogénicas c-myc/análisis , Animales , Supervivencia Celular , Centro Germinal/fisiología , Ratones , Ratones Endogámicos C57BL , MicroARNs/análisis , Complejo Represivo Polycomb 2/fisiología
10.
Science ; 352(6292): aad1210, 2016 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-27313051

RESUMEN

The NLRP3 inflammasome controls interleukin-1ß maturation in antigen-presenting cells, but a direct role for NLRP3 in human adaptive immune cells has not been described. We found that the NLRP3 inflammasome assembles in human CD4(+) T cells and initiates caspase-1-dependent interleukin-1ß secretion, thereby promoting interferon-γ production and T helper 1 (T(H)1) differentiation in an autocrine fashion. NLRP3 assembly requires intracellular C5 activation and stimulation of C5a receptor 1 (C5aR1), which is negatively regulated by surface-expressed C5aR2. Aberrant NLRP3 activity in T cells affects inflammatory responses in human autoinflammatory disease and in mouse models of inflammation and infection. Our results demonstrate that NLRP3 inflammasome activity is not confined to "innate immune cells" but is an integral component of normal adaptive T(H)1 responses.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Proteínas Portadoras/metabolismo , Complemento C5a/inmunología , Inflamasomas/inmunología , Interferón gamma/biosíntesis , Células TH1/inmunología , Inmunidad Adaptativa , Animales , Comunicación Autocrina , Proteínas Portadoras/genética , Activación de Complemento , Síndromes Periódicos Asociados a Criopirina/inmunología , Modelos Animales de Enfermedad , Células HEK293 , Humanos , Inmunidad Innata , Inflamación/inmunología , Proteína Cofactora de Membrana/inmunología , Ratones , Ratones Mutantes , Proteína con Dominio Pirina 3 de la Familia NLR , Especies Reactivas de Oxígeno/metabolismo , Receptor de Anafilatoxina C5a/agonistas , Receptor de Anafilatoxina C5a/antagonistas & inhibidores , Receptor de Anafilatoxina C5a/metabolismo , Receptores de Antígenos de Linfocitos T/agonistas , Receptores de Antígenos de Linfocitos T/metabolismo , Receptores de Quimiocina/agonistas , Receptores de Quimiocina/antagonistas & inhibidores , Receptores de Quimiocina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA